Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
Caine
Graham J
GJ
Lip
Gregory Y H
GY
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004617:Embolism / Q000401:mortality / Q000517:prevention & control*; D023381:Endpoint Determination; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000401:mortality / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin